Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Pliant Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Bernard Coulie
İcra Kurulu Başkanı
US$11.2m
Toplam tazminat
CEO maaş yüzdesi | 5.5% |
CEO görev süresi | 8.7yrs |
CEO sahipliği | 1.1% |
Yönetim ortalama görev süresi | 8.6yrs |
Yönetim Kurulu ortalama görev süresi | 7yrs |
Son yönetim güncellemeleri
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$185m |
Mar 31 2024 | n/a | n/a | -US$171m |
Dec 31 2023 | US$11m | US$610k | -US$161m |
Sep 30 2023 | n/a | n/a | -US$155m |
Jun 30 2023 | n/a | n/a | -US$144m |
Mar 31 2023 | n/a | n/a | -US$133m |
Dec 31 2022 | US$11m | US$587k | -US$123m |
Sep 30 2022 | n/a | n/a | -US$113m |
Jun 30 2022 | n/a | n/a | -US$109m |
Mar 31 2022 | n/a | n/a | -US$103m |
Dec 31 2021 | US$5m | US$556k | -US$97m |
Sep 30 2021 | n/a | n/a | -US$92m |
Jun 30 2021 | n/a | n/a | -US$81m |
Mar 31 2021 | n/a | n/a | -US$75m |
Dec 31 2020 | US$2m | US$499k | -US$42m |
Sep 30 2020 | n/a | n/a | US$18m |
Jun 30 2020 | n/a | n/a | US$19m |
Mar 31 2020 | n/a | n/a | US$20m |
Dec 31 2019 | US$2m | US$428k | -US$7m |
Tazminat ve Piyasa: Bernard 'nin toplam tazminatı ($USD 11.17M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.23M ).
Tazminat ve Kazançlar: Bernard şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Bernard Coulie (57 yo)
8.7yrs
Görev süresi
US$11,165,999
Tazminat
Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Director of Septerna, Inc. from February 2024. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairm...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | no data | US$11.17m | 1.1% $ 7.7m | |
Chief Financial Officer | 5.8yrs | US$4.44m | 0.31% $ 2.2m | |
General Counsel & Corporate Secretary | 4yrs | US$3.32m | 0.060% $ 421.3k | |
Chief Business Officer | 8.6yrs | US$4.36m | 0.32% $ 2.2m | |
Chief Medical Officer | 6.4yrs | US$4.69m | 0.22% $ 1.5m | |
Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | Veri yok | Veri yok | |
Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | Veri yok | Veri yok | |
Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | Veri yok | Veri yok | |
Scientific Founder & Member of Scientific Advisory Board | 9.8yrs | Veri yok | Veri yok | |
Interim Chief Technology Officer | no data | Veri yok | Veri yok | |
Vice President of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok | |
Chief Human Resources Officer | 1.8yrs | Veri yok | 0.0013% $ 9.2k |
8.6yrs
Ortalama Görev Süresi
51yo
Ortalama Yaş
Deneyimli Yönetim: PLRX 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.6 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
President | 8.7yrs | US$11.17m | 1.1% $ 7.7m | |
Scientific Founder & Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Scientific Founder & Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Scientific Founder & Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Scientific Founder & Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Independent Director | 4.8yrs | US$278.71k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
Independent Director | 8.3yrs | US$277.21k | 0.058% $ 404.5k | |
Independent Director | 7.2yrs | US$271.96k | 0.048% $ 337.6k | |
Independent Chairman | 6.8yrs | US$296.71k | 0.16% $ 1.2m | |
Independent Director | 5.6yrs | US$277.96k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
7.0yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: PLRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).